Login to Your Account



ProtAffin Gets €14M for Engineered Chemokines

By Cormac Sheridan


Wednesday, April 29, 2009

No Abstract

 

BioWorld International Correspondent

ProtAffin AG raised €14 million (US$18.3 million) in a Series B round to progress its early stage pipeline of novel, protein-based therapeutics that act by disrupting biological signaling between extracellular glycan structures and their protein ligands.

The Graz, Austria-based company is adding 11 new staff on the strength of the new funding, boosting total headcount to 27 people.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription